ETCTN Trials by Disease/ Treatment Area: Sarcoma

**10005:** A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

**10015:** A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

**10056:** A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

**10330:** A Phase II Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

**10398:** A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

**10387:** Phase I Trial of Nivolumab plus Cabozantinib for Advanced Solid Tumors in Patients with HIV infection (Dose-Escalation: advanced solid tumors in patients with HIV infection; Expansion cohort: Kaposi’s sarcoma) NEW!!

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: February 17, 2020